Loading...

ProMIS Neurosciences

DB:23J
Snowflake Description

Adequate balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
23J
DB
CA$71M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
  • ProMIS Neurosciences has significant price volatility in the past 3 months.
23J Share Price and Events
7 Day Returns
-3.8%
DB:23J
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-34.6%
DB:23J
-9.2%
DE Biotechs
-6.7%
DE Market
23J Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ProMIS Neurosciences (23J) -3.8% -25.1% 4.1% -34.6% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 23J underperformed the Biotechs industry which returned -9.2% over the past year.
  • 23J underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
23J
Industry
5yr Volatility vs Market

Value

 Is ProMIS Neurosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ProMIS Neurosciences. This is due to cash flow or dividend data being unavailable. The share price is €0.176.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ProMIS Neurosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ProMIS Neurosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:23J PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CAD CA$-0.04
TSX:PMN Share Price ** TSX (2019-04-18) in CAD CA$0.28
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ProMIS Neurosciences.

DB:23J PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:PMN Share Price ÷ EPS (both in CAD)

= 0.28 ÷ -0.04

-6.47x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ProMIS Neurosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ProMIS Neurosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ProMIS Neurosciences's expected growth come at a high price?
Raw Data
DB:23J PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.47x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-6.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ProMIS Neurosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ProMIS Neurosciences's assets?
Raw Data
DB:23J PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CAD CA$0.00
TSX:PMN Share Price * TSX (2019-04-18) in CAD CA$0.28
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:23J PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:PMN Share Price ÷ Book Value per Share (both in CAD)

= 0.28 ÷ 0.00

58.71x

* Primary Listing of ProMIS Neurosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ProMIS Neurosciences is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ProMIS Neurosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ProMIS Neurosciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ProMIS Neurosciences expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-6.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ProMIS Neurosciences expected to grow at an attractive rate?
  • Unable to compare ProMIS Neurosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare ProMIS Neurosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • ProMIS Neurosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:23J Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:23J Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -6.5%
DB:23J Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 18.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:23J Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:23J Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 0 -15 -16 1
2022-12-31 0 -22 -14 1
2021-12-31 0 -10 -12 1
2020-12-31 0 34 -15 1
2019-12-31 0 -9 -14 1
DB:23J Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -9 -10
2018-09-30 0 -7 -8
2018-06-30 0 -6 -7
2018-03-31 0 -6 -6
2017-12-31 0 -6 -6
2017-09-30 0 -5 -6
2017-06-30 0 -4 -5
2017-03-31 0 -3 -4
2016-12-31 0 -3 -3
2016-09-30 0 -2 -3
2016-06-30 0 -3 -3
2016-03-31 0 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ProMIS Neurosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • ProMIS Neurosciences's revenue is expected to grow by 18.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:23J Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from ProMIS Neurosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:23J Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.03 -0.03 -0.03 1.00
2022-12-31 -0.04 -0.04 -0.04 1.00
2021-12-31 -0.03 -0.03 -0.03 1.00
2020-12-31 -0.04 -0.03 -0.06 2.00
2019-12-31 -0.05 -0.04 -0.06 2.00
DB:23J Past Financials Data
Date (Data in CAD Millions) EPS *
2018-12-31 -0.04
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 -0.03
2017-12-31 -0.03
2017-09-30 -0.03
2017-06-30 -0.03
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.02
2016-06-30 -0.02
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ProMIS Neurosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ProMIS Neurosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ProMIS Neurosciences has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ProMIS Neurosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ProMIS Neurosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ProMIS Neurosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ProMIS Neurosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ProMIS Neurosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ProMIS Neurosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ProMIS Neurosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:23J Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.00 -10.17 2.76
2018-09-30 0.00 -7.81 2.84
2018-06-30 0.01 -6.52 2.18
2018-03-31 0.01 -6.20 2.18
2017-12-31 0.01 -6.02 2.32
2017-09-30 0.01 -6.11 2.32
2017-06-30 0.00 -5.35 2.30
2017-03-31 0.00 -4.16 1.90
2016-12-31 0.00 -3.45 1.58
2016-09-30 0.00 -2.94 1.41
2016-06-30 0.01 -2.80 1.39
2016-03-31 0.01 -2.36 1.15
2015-12-31 0.02 -2.12 0.95
2015-09-30 0.08 -1.94 0.83
2015-06-30 0.13 -1.93 0.82
2015-03-31 0.27 -2.57 1.18
2014-12-31 0.31 -2.89 1.54
2014-09-30 0.28 -2.81 1.58
2014-06-30 0.25 -2.57 1.41
2014-03-31 0.15 -2.25 0.99
2013-12-31 0.13 -2.06 0.71 -0.89
2013-09-30 0.11 -2.12 0.68 -0.82
2013-06-30 0.08 -2.23 0.69 -0.41
2013-03-31 0.05 -2.23 0.68
2012-12-31 0.02 -2.38 0.68 1.71
2012-09-30 0.02 -2.61 0.71 1.92
2012-06-30 0.06 -2.61 0.65 2.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ProMIS Neurosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ProMIS Neurosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ProMIS Neurosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ProMIS Neurosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ProMIS Neurosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ProMIS Neurosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ProMIS Neurosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ProMIS Neurosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ProMIS Neurosciences has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ProMIS Neurosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ProMIS Neurosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ProMIS Neurosciences Company Filings, last reported 3 months ago.

DB:23J Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1.16 0.00 2.43
2018-09-30 4.45 0.00 4.69
2018-06-30 6.77 0.00 6.85
2018-03-31 1.85 0.00 1.69
2017-12-31 1.53 0.00 1.73
2017-09-30 2.60 0.00 3.33
2017-06-30 -0.08 0.12 0.72
2017-03-31 1.65 0.12 2.07
2016-12-31 0.07 0.12 0.75
2016-09-30 1.10 0.12 1.53
2016-06-30 0.38 0.12 0.75
2016-03-31 0.63 0.11 1.06
2015-12-31 0.60 0.12 0.94
2015-09-30 1.10 0.11 1.42
2015-06-30 -0.89 0.10 0.00
2015-03-31 -0.63 0.00 0.01
2014-12-31 -0.20 0.00 0.03
2014-09-30 -0.08 0.00 0.07
2014-06-30 0.43 0.00 0.43
2014-03-31 0.01 0.00 0.14
2013-12-31 -0.51 0.00 0.05
2013-09-30 -0.34 0.00 0.01
2013-06-30 0.03 0.00 0.14
2013-03-31 -0.22 0.00 0.04
2012-12-31 0.15 0.00 0.13
2012-09-30 0.64 0.00 0.58
2012-06-30 1.20 0.00 1.18
  • ProMIS Neurosciences has no debt.
  • ProMIS Neurosciences had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ProMIS Neurosciences has less than a year of cash runway based on current free cash flow.
  • ProMIS Neurosciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 51.7% each year.
X
Financial health checks
We assess ProMIS Neurosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ProMIS Neurosciences has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ProMIS Neurosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ProMIS Neurosciences dividends.
If you bought €2,000 of ProMIS Neurosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ProMIS Neurosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ProMIS Neurosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:23J Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:23J Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ProMIS Neurosciences has not reported any payouts.
  • Unable to verify if ProMIS Neurosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ProMIS Neurosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ProMIS Neurosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ProMIS Neurosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ProMIS Neurosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ProMIS Neurosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ProMIS Neurosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Elliot Goldstein
COMPENSATION CA$470,389
AGE 67
TENURE AS CEO 3.8 years
CEO Bio

Dr. Elliot Goldstein, M.D. has been the Chief Executive Officer and President of ProMIS Neurosciences Inc. (Alternate name -Amorfix Life Sciences Ltd.) since July 2015 respectively. Dr. Goldstein is a Co-Founder of Vitrua, LLC. He served as Consulting Chief Medical Officer at Immune Pharmaceuticals, Inc. since April 02, 2014. He served as the Chief Medical Officer of Dart Therapeutics, LLC (now Akashi Therapeutics, Inc.) since September 2012. He has a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. He has more than 30 years of executive-level pharmaceutical and biotechnology expertise. Dr. Goldstein served as Chief Operating Officer of Maxygen Inc., from January 2006 to November 2009 and served as its Chief Medical Officer. Dr. Goldstein served as Senior Vice President, Clinical Development and Danish Operations of Maxygen Inc. from February 2003 to January 2006. He served as the Chief Executive Officer of Vernalis PLC from September 1998 to November 2002. He served as the Senior Vice President and Director, Worldwide Strategic Product Development at SmithKline Beecham from 1994 to 1998. From 1980 to 1994, he held a variety of senior level positions at Sandoz, a pharmaceutical company, in France, Switzerland and the U.S. including Vice President, Clinical Research and Development at Sandoz Research Institute. Dr. Goldstein served as Chief Operating Officer/Chief Medical Officer at Maxigen, Inc. where he was responsible for the successful execution of all key operating functions, including process development, pharmacology/biology, molecular biology, clinical/regulatory, project management and quality assurance. Dr. Goldstein began his career with Sandoz Pharmaceuticals (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters and including as Head of Clinical R&D in the United States. He served at Novartis. He has been Director of Amorfix Life Sciences Ltd. since September 29, 2014. He served as a Director of Vernalis PLC (formerly, British Biotechnology PLC). Dr. Goldstein obtained his M.D. from the University of Aix-Marseille, France in 1979, graduated in 1972 with a B.Sc. in genetics from McGill University, Montreal.

CEO Compensation
  • Elliot's compensation has increased whilst company is loss making.
  • Elliot's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ProMIS Neurosciences management team in years:

2.8
Average Tenure
63.5
Average Age
  • The tenure for the ProMIS Neurosciences management team is about average.
Management Team

Gene Williams

TITLE
Executive Chairman
COMPENSATION
CA$470K
AGE
59
TENURE
3.8 yrs

Elliot Goldstein

TITLE
President
COMPENSATION
CA$470K
AGE
67
TENURE
3.8 yrs

Neil Cashman

TITLE
Founder
COMPENSATION
CA$105K

Dan Geffken

TITLE
Chief Financial Officer
COMPENSATION
CA$162K
AGE
61
TENURE
2.1 yrs

Johanne Kaplan

TITLE
Chief Development Officer
COMPENSATION
CA$229K
TENURE
2.8 yrs

Warren Whitehead

TITLE
Special Adviser
AGE
66
TENURE
3.8 yrs

Steven Plotkin

TITLE
Chief Physics Officer
TENURE
3.6 yrs

Ernie Bush

TITLE
Head of Pharmacology/Toxicology
TENURE
1 yrs

Russell Blacher

TITLE
Head of Manufacturing
TENURE
1 yrs

Jim Kupiec

TITLE
Chief Medical Officer
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the ProMIS Neurosciences board of directors in years:

3.8
Average Tenure
60.5
Average Age
  • The tenure for the ProMIS Neurosciences board of directors is about average.
Board of Directors

Gene Williams

TITLE
Executive Chairman
COMPENSATION
CA$470K
AGE
59
TENURE
3.8 yrs

Elliot Goldstein

TITLE
President
COMPENSATION
CA$470K
AGE
67
TENURE
4.6 yrs

Neil Cashman

TITLE
Founder
COMPENSATION
CA$105K
TENURE
12.3 yrs

Rich Gregory

TITLE
Independent Director
AGE
60
TENURE
2.5 yrs

Todd Golde

TITLE
Co-Chair of Scientific Advisory Board

Johannes Roth

TITLE
Independent Director
AGE
39
TENURE
5.3 yrs

Bill Wyman

TITLE
Independent Director
AGE
80
TENURE
5.1 yrs

Patrick Kirwin

TITLE
Independent Director
TENURE
3.8 yrs

Anthony Giovinazzo

TITLE
Independent Director
COMPENSATION
CA$423K
AGE
61
TENURE
2.1 yrs

William Mobley

TITLE
Member of Scientific Advisory Board
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by ProMIS Neurosciences insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
30. Jan 19 Buy Johanne Kaplan Individual 23. Jan 19 23. Jan 19 289,017 €0.15 €43,900
23. Jan 19 Buy Eugene Williams Individual 22. Jan 19 22. Jan 19 115,607 €0.15 €17,555
23. Jan 19 Buy Anthony Giovinazzo Individual 22. Jan 19 22. Jan 19 325,000 €0.15 €49,352
23. Jan 19 Buy Elliot Goldstein Individual 22. Jan 19 22. Jan 19 115,607 €0.15 €17,555
17. Aug 18 Buy Anthony Giovinazzo Individual 15. Aug 18 15. Aug 18 200,000 €0.19 €36,450
09. Aug 18 Buy Anthony Giovinazzo Individual 03. Aug 18 03. Aug 18 18,000 €0.22 €3,947
01. May 18 Buy Eugene Williams Individual 30. Apr 18 30. Apr 18 66,666 €0.24 €16,146
01. May 18 Buy Elliot Goldstein Individual 30. Apr 18 30. Apr 18 66,666 €0.24 €16,146
01. May 18 Buy William Wyman Individual 30. Apr 18 30. Apr 18 333,333 €0.24 €80,731
X
Management checks
We assess ProMIS Neurosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ProMIS Neurosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody for AD; PMN350, a monoclonal antibody for AD; and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing prospect therapies targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS and frontotemporal dementia, as well as alpha synuclein in Parkinson’s disease and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Details
Name: ProMIS Neurosciences, Inc.
23J
Exchange: DB
Founded: 2004
CA$46,895,717
256,389,069
Website: http://www.promisneurosciences.com
Address: ProMIS Neurosciences, Inc.
1920 Yonge Street,
Suite 200,
Toronto,
Ontario, M4S 3E2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX PMN Common Shares The Toronto Stock Exchange CA CAD 03. Oct 2005
OTCPK ARFX.F Common Shares Pink Sheets LLC US USD 03. Oct 2005
DB 23J Common Shares Deutsche Boerse AG DE EUR 03. Oct 2005
Number of employees
Current staff
Staff numbers
0
ProMIS Neurosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:31
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/21
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.